^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    NRG3 deletion

    i
    Other names: NRG3, Neuregulin 3, Pro-Neuregulin-3, Membrane-Bound Isoform, Pro-NRG3, Neuregulin-3-Like Polypeptide, HRG3
    Entrez ID:
    10718
    Related biomarkers:
    Fusion
    1year
    Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting. (PubMed, Acta Neuropathol Commun)
    All patients in our discovery cohort received radiation, all but one underwent chemotherapy, and no patient received temozolomide (TMZ) before progression to grade 4 disease...In our retrospective analysis of patient treatment and survival timelines (n = 75), the combination of postoperative radiation and chemotherapy (mainly TMZ) outperformed radiation, especially in the grade 3 tumor cohort, in which it was typically given after primary surgery. Our results provide further insight into the contribution of treatment and genetic alterations in cell cycle, growth factor signaling, and DNA repair-related genes to tumor evolution and progression.
    Journal
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • DNMT3A (DNA methyltransferase 1) • RB1 (RB Transcriptional Corepressor 1) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • MSH2 (MutS Homolog 2) • RAD51B (RAD51 Paralog B) • NRG3 (Neuregulin 3)
    |
    CDKN2A deletion • MSH2 mutation • NRG3 deletion
    |
    temozolomide